Trump Announces Landmark Agreement to Slash Weight-Loss Drug Costs

Historic Agreement on Weight-Loss Drugs

• 🎯 President Trump announced a groundbreaking agreement with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to drastically reduce the cost of popular GLP-1 weight-loss drugs, such as Zepbound and Wegovy.
• 💡 The agreement aims to cut prices by 200% to 700%, bringing monthly costs down from over $1,000 to as low as $250 for Wegovy and $346 for Zepbound.
• 🚀 Future oral GLP-1 weight-loss drugs are slated to cost no more than $149 per month.

Addressing Healthcare Inequity and Costs

• 💰 The initiative is framed as a triumph for American patients, addressing the "chronic unfairness" where Americans pay significantly more for prescription drugs than patients in other countries.
• ⚖️ This agreement aligns with the "Most Favored Nations" (MFN) drug pricing policy, ensuring Americans pay no more than the lowest price offered globally.
• 📈 Previously, Americans paid up to 520% more for Zepbound and 1400% more for Wegovy than European patients.

Expanded Access and Coverage

• ✅ Medicare and Medicaid will now cover the costs of these weight-loss drugs for millions of patients suffering from obesity, with co-pays for Medicare patients as low as $50 per month.
• 🌐 Drugs will be available directly to consumers via TrumpRx.gov, with pricing expected to be significantly lower than current market rates.
• 🌍 Eli Lilly and Novo Nordisk have also agreed to provide all their other medications to Medicaid at MFN prices and offer discounted prices to all consumers.

Economic and Health Impact

• 🇺🇸 Pharmaceutical companies Eli Lilly and Novo Nordisk are committing to significant investments in domestic manufacturing, with $27 billion and $10 billion, respectively.
• 📊 Projections estimate that Americans could collectively lose 135 million pounds by the midterms due to increased access to these medications.
• 🩺 The agreement is presented as a critical tool in combating chronic diseases, with obesity identified as a primary driver of conditions like diabetes and heart disease.

Policy and Negotiation

• 🤝 The agreement was facilitated by an executive order on MFN pricing and months of negotiations, with officials emphasizing the collaborative effort between the administration and pharmaceutical leaders.
• 🗣️ President Trump highlighted his administration's success in making healthcare affordable, contrasting it with previous political promises and the current administration's approach.
• 🌟 The CEOs of Eli Lilly and Novo Nordisk were praised for their cooperation and for aligning company interests with public health outcomes.